Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3.
GSK-3
PET imaging
copper-mediated radiofluorination
fluorine-18
glycogen synthase kinase 3
neuroimaging
Journal
Journal of fluorine chemistry
ISSN: 0022-1139
Titre abrégé: J Fluor Chem
Pays: United States
ID NLM: 0373322
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
ppublish
Résumé
Glycogen synthase kinase 3 (GSK-3) is an enzyme that is dysregulated in oncology neurodegeneration, neuroinflammation and several mental health illnesses. As such, GSK-3 is a long-sought after target for positron emission tomography (PET) imaging and therapeutic intervention. Herein, we report on the development and radiofluorination of two oxazole-4-carboxamides, including one bearing a non-activated aromatic ring. Both compounds demonstrated excellent selectivity in a kinase screen and inhibit GSK-3 with high affinity. [
Identifiants
pubmed: 33840834
doi: 10.1016/j.jfluchem.2021.109760
pmc: PMC8034590
mid: NIHMS1680899
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIA NIH HHS
ID : R01 AG052414
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054473
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB021155
Pays : United States
Déclaration de conflit d'intérêts
Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
ACS Med Chem Lett. 2015 Mar 10;6(5):548-52
pubmed: 26005531
Bioconjug Chem. 2016 May 18;27(5):1382-9
pubmed: 27043721
Brain Inj. 1999 Jan;13(1):1-13
pubmed: 9972437
Org Lett. 2015 Dec 4;17(23):5780-3
pubmed: 26568457
Chem Sci. 2014 Dec 1;5(12):4545-4553
pubmed: 25379166
J Neurotrauma. 2016 Dec 1;33(23):2065-2076
pubmed: 26979735
Trends Pharmacol Sci. 2004 Sep;25(9):471-80
pubmed: 15559249
J Med Chem. 2019 Nov 14;62(21):9600-9617
pubmed: 31535859
Clin Transl Imaging. 2020 Jun;8(3):167-206
pubmed: 33748018
Theranostics. 2016 Feb 17;6(4):571-93
pubmed: 26941849
Trends Pharmacol Sci. 2003 Sep;24(9):441-3
pubmed: 12967765
Int J Alzheimers Dis. 2011;2011:189246
pubmed: 21629738
EMBO J. 1990 Aug;9(8):2431-8
pubmed: 2164470
ACS Med Chem Lett. 2017 Feb 02;8(3):287-292
pubmed: 28337318
Nat Rev Neurosci. 2010 Aug;11(8):539-51
pubmed: 20648061
Angew Chem Int Ed Engl. 2019 Feb 25;58(9):2580-2605
pubmed: 30054961
Molecules. 2010 Nov 15;15(11):8260-78
pubmed: 21079565
Sci Rep. 2017 Mar 22;7(1):233
pubmed: 28331174
J Neurochem. 2008 Mar;104(6):1433-9
pubmed: 18088381
Bioorg Med Chem Lett. 2005 Dec 1;15(23):5270-3
pubmed: 16202587
Trends Biochem Sci. 2004 Feb;29(2):95-102
pubmed: 15102436
ACS Chem Neurosci. 2017 Aug 16;8(8):1697-1703
pubmed: 28485573
Angew Chem Int Ed Engl. 2016 Aug 8;55(33):9601-5
pubmed: 27355874
J Nucl Med. 2018 Apr;59(4):568-572
pubmed: 29284673
Curr Top Med Chem. 2013;13(15):1808-19
pubmed: 23931441
Sci Rep. 2019 Aug 6;9(1):11370
pubmed: 31388076
Bioorg Med Chem Lett. 2019 Mar 15;29(6):778-781
pubmed: 30709652
Front Mol Neurosci. 2011 Oct 31;4:32
pubmed: 22065134
ACS Chem Neurosci. 2010 Jun 16;1(6):435-49
pubmed: 22778837
Nucl Med Biol. 2014 Jul;41(6):507-12
pubmed: 24768148
Bioorg Med Chem Lett. 2015 Aug 15;25(16):3230-3
pubmed: 26067173
Nat Immunol. 2005 Aug;6(8):777-84
pubmed: 16007092